The fundamental question is how will a delay in treatment affect outcomes. Treatment delays may lower the risk of contracting and dying of COVID-19 by allowing the peak of the pandemic to pass, but they have the potential to increase cancer-specific mortality (CSM). Our team has created an integrated model to provide quantitative estimates of the net impact of treatment delay on overall mortality (<http://onccovid.med.umich.edu/>).

Using the following assumptions, if the patient has 1 additional comorbid condition and lives in San Mateo, California, and assuming a COVID-19 replication rate (R~0~) of 2,[@bib1] we would estimate the patient's1.5-year CSM pre--COVID-19 to be 3.2%.2.5-year overall mortality pre--COVID-19 to be 16.7% (CSM + other-cause of mortality).3.age- and comorbidity-adjusted COVID-19--specific mortality to be 13.9%.4.hazard ratio for treatment delay on CSM to be 1.0 (multiple data sets confirm this).

The integrated impact of a 3-month delay would result in an improvement in his restricted mean survival time of only 9 days over a 5-year period, something incredibly small.

Thus, I would have treated the patient in early March with stereotactic body radiation therapy and androgen deprivation therapy (ADT) because of the known survival benefits of ADT, the potential protective effect of ADT on COVID-19--specific mortality, and because the patient is estimated to live \>10 years. Now that his treatment has been delayed, I would treat him with shorter-term ADT based on the DART 01/05 randomized trial, which demonstrated that long-term ADT increased cardiovascular events by 2.1-fold and the dominant mode of death in high-risk prostate cancer is other-cause mortality.[@bib2] I would continue to offer stereotactic body radiation therapy to reduce hospital exposure to COVID-19 if it is in the peak of a second wave (estimated 7% increased risk of contracting COVID-19 from 5- vs 20-fraction radiation therapy from increased cumulative hospital exposure). I would not give nodal radiation therapy based multiple negative randomized trials, while we await the results of RTOG 0924.[@bib3]

Disclosures: D.E.S. served on advisory boards for Janssen, AstraZeneca, and Blue Earth.

What would you do? Continue the discussion on Twitter at [\#gyzone](http://ctt.ec/pi683){#interref0010rdf}, and take the poll at [www.redjournal.org/poll](http://www.redjournal.org/poll){#interref0010}.
